On May 20, 2026, Polpharma inaugurated a 238.7 million PLN investment in Starogard Gdański, establishing Poland’s first comprehensive, end-to-end platform for the development and production of RNA-based medicines.
A Strategic Leap for RNA Medicine
The development of RNA technology marks a significant breakthrough, enabling medical interventions directly at the genetic source. Rather than targeting proteins that have already formed, this approach interferes with genetic information or its expression, allowing for the blockage of harmful proteins or the instruction of the body to produce healthy ones.
By investing in this field, Poland joins a select group of nations developing advanced therapeutic technologies. This infrastructure project, supported by public funding and scientific partnerships, strengthens the country’s drug security and technological independence.
A Comprehensive End-to-End Platform
The project is uniquely defined by its end-to-end nature, covering the entire value chain from active pharmaceutical ingredient (API) synthesis to process development, analytics, and final product manufacturing. Polpharma is currently the only entity in Poland that integrates API development and final product creation within the RNA sector.
The total investment of 238.7 million PLN includes 152 million PLN in company capital and 86.7 million PLN from public sources, specifically the Medical Research Agency (ABM) and the National Centre for Research and Development (NCBiR).
Flexible Production for Global Competitiveness
The new infrastructure utilizes Single Use Systems, offering the flexibility to handle everything from small batches for rare disease therapies to larger production volumes. This agility is crucial for meeting clinical development timelines and maintaining high quality standards.
This initiative directly addresses the global market reliance on non-EU, particularly Asian, suppliers for oligonucleotide production. By building these capabilities locally, Polpharma aims to shift Poland from a consumer of RNA technology to an active co-developer and exporter, enhancing the nation’s standing in the European biotechnology sector.
